SEC 13F Intelligence

Capital Research Global Investors / TEVA

Capital Research Global Investors’s Teva Pharmaceutical Inds Ltd Position

Does Capital Research Global Investors own Teva Pharmaceutical Inds Ltd (TEVA)? Not currently — the last reported position was 82.64M shares worth $731M in Q1 2023; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$731M
Q1 2023
Shares
82.64M
% of Portfolio
+0.21%
Quarters Held
18
position exited

Position History TEVA

Reported value by quarter
Q4 ’18: $1.9BQ4 ’18Q1 ’19: $2.0BQ2 ’19: $1.2BQ3 ’19: $901MQ3 ’19Q4 ’19: $1.3BQ1 ’20: $1.2BQ2 ’20: $1.6BQ2 ’20Q3 ’20: $1.2BQ4 ’20: $1.3BQ1 ’21: $1.5BQ1 ’21Q2 ’21: $1.2BQ3 ’21: $1.2BQ4 ’21: $1.1BQ4 ’21Q1 ’22: $1.2BQ2 ’22: $701MQ3 ’22: $946MQ3 ’22Q4 ’22: $1.0BQ1 ’23: $731Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 202382.64M$731M+0.21%
Q4 2022114.79M$1.0B+0.32%
Q3 2022117.19M$946M+0.31%
Q2 202293.17M$701M+0.22%
Q1 2022132.17M$1.2B+0.31%
Q4 2021132.35M$1.1B+0.23%
Q3 2021118.88M$1.2B+0.27%
Q2 2021122.65M$1.2B+0.28%
Q1 2021128.69M$1.5B+0.36%
Q4 2020130.14M$1.3B+0.33%
Q3 2020130.11M$1.2B+0.35%
Q2 2020130.13M$1.6B+0.51%
Q1 2020130.09M$1.2B+0.46%
Q4 2019130.95M$1.3B+0.38%
Q3 2019130.93M$901M+0.30%
Q2 2019130.89M$1.2B+0.38%
Q1 2019128.19M$2.0B+0.64%
Q4 2018121.95M$1.9B+0.66%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Capital Research Global Investors’s full portfolio or all institutional holders of TEVA.